Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Risk adjusted net present value: What is the current valuation of Merck's MK-2060?
MK-2060 is a monoclonal antibody commercialized by Merck, with a leading Phase II program in Thrombosis. According to Globaldata, it...